Floatz logo

Tazemetostat

Low Grade Glioma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Low Grade Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2BB
FET
Thomas Hope
Phase 2B
Olaparib
National Cancer Institute (NCI)
Phase 2B
Binimetinib
National Cancer Center, Japan
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC

View all 14 →

Same molecule, other indications

Tazemetostat is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
epithelioid sarcomaDormant
BB
Indicative ·
70 / 100
View asset →
kidney medullary carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →